The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDirecta Plus Regulatory News (DCTA)

Share Price Information for Directa Plus (DCTA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.00
Bid: 18.00
Ask: 20.00
Change: 0.00 (0.00%)
Spread: 2.00 (11.111%)
Open: 19.00
High: 19.00
Low: 19.00
Prev. Close: 19.00
DCTA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of US Patent

27 Jun 2019 07:00

RNS Number : 5527D
Directa Plus PLC
27 June 2019
 

27 June 2019

 

Directa Plus plc

("Directa Plus" or the "Company")

 

US Patent Grant

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, is pleased to announce the grant of a key patent, relating to the Company's unique manufacturing process, by the United States Patent and Trademark Office.

 

The new US patent covers Directa Plus' unique process for manufacturing graphene nanoplatelets using a water-based exfoliation technology. The process is sustainable and environmentally friendly as a result of using no chemicals, solvents or surfactants and generating zero waste. The manufacturing process allows the Company to engineer a wide range of particle morphologies that can be tailored to the particular requirements of end-user customers. In addition, the 100 per cent production yield means that Directa Plus can manufacture products in large volumes at attractive prices. This provides a significant competitive advantage, enabling the Company to integrate effectively and quickly with customers' large supply chains.

 

Commenting on the grant, Giulio Cesareo, Founder and CEO of Directa Plus, said: "This grant represents a key development in launching our products into the United States. The sustainable nature of our production process, using no chemicals, is proving to be an attractive point of difference in negotiations with large US companies."

 

For further information please visit http://www.directa-plus.com/ or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO

 

Marco Ferrari, CFO

 

 

 

Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)

+44 20 7894 7000

Rick Thompson, Philip Davies Will Goode (Corporate Finance)

 

Caspar Shand Kydd (Sales)

 

 

 

N+1 Singer (Joint Broker)

+44 20 7496 3069

Mark Taylor, Lauren Kettle

 

 

 

Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson, Barnaby Hayward, Edward Lee

 

 

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products). In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products. All our products are hypoallergenic, non-toxic and sustainably produced.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRALLFVERRIRFIA
Date   Source Headline
18th Aug 20167:00 amRNSChange of Registered Address
14th Jul 20164:04 pmRNSHolding(s) in Company
7th Jun 20164:35 pmRNSPrice Monitoring Extension
2nd Jun 20164:40 pmRNSSecond Price Monitoring Extn
2nd Jun 20164:35 pmRNSPrice Monitoring Extension
27th May 20164:09 pmRNSHolding(s) in Company
27th May 20168:01 amRNSAdmission and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.